Otsuka Holdings Co., Ltd. (OTSKF)
USD 57.15
(0.0%)
USD 57.15
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 924.92 Billion JPY | 10.09% |
| 2022 | 840.16 Billion JPY | 8.31% |
| 2021 | 775.72 Billion JPY | 4.21% |
| 2020 | 744.37 Billion JPY | -5.28% |
| 2019 | 785.87 Billion JPY | 5.58% |
| 2018 | 744.36 Billion JPY | 13.07% |
| 2017 | 658.3 Billion JPY | -11.02% |
| 2016 | 739.84 Billion JPY | -12.45% |
| 2015 | 845.07 Billion JPY | 52.82% |
| 2014 | 553 Billion JPY | 21.77% |
| 2013 | 454.13 Billion JPY | 2.28% |
| 2012 | 444 Billion JPY | 4.13% |
| 2011 | 426.39 Billion JPY | -16.38% |
| 2010 | 509.91 Billion JPY | 17.23% |
| 2009 | 434.97 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 894.52 Billion JPY | -3.29% |
| 2024 Q2 | 993.85 Billion JPY | 11.1% |
| 2023 FY | 924.92 Billion JPY | 10.09% |
| 2023 Q2 | 840.26 Billion JPY | 3.55% |
| 2023 Q3 | 892.18 Billion JPY | 6.18% |
| 2023 Q4 | 924.92 Billion JPY | 3.67% |
| 2023 Q1 | 811.45 Billion JPY | -3.42% |
| 2022 Q2 | 839.53 Billion JPY | 7.34% |
| 2022 Q1 | 782.09 Billion JPY | 0.82% |
| 2022 Q3 | 853.31 Billion JPY | 1.64% |
| 2022 FY | 840.16 Billion JPY | 8.31% |
| 2022 Q4 | 840.16 Billion JPY | -1.54% |
| 2021 FY | 775.72 Billion JPY | 4.21% |
| 2021 Q3 | 798.15 Billion JPY | 8.94% |
| 2021 Q4 | 775.72 Billion JPY | -2.81% |
| 2021 Q1 | 742.34 Billion JPY | -0.27% |
| 2021 Q2 | 732.63 Billion JPY | -1.31% |
| 2020 Q1 | 760.03 Billion JPY | -3.29% |
| 2020 Q2 | 746.01 Billion JPY | -1.85% |
| 2020 Q3 | 727.97 Billion JPY | -2.42% |
| 2020 Q4 | 744.37 Billion JPY | 2.25% |
| 2020 FY | 744.37 Billion JPY | -5.28% |
| 2019 Q2 | 861.8 Billion JPY | -2.23% |
| 2019 Q4 | 785.87 Billion JPY | -8.11% |
| 2019 Q1 | 881.44 Billion JPY | 18.41% |
| 2019 Q3 | 855.26 Billion JPY | -0.76% |
| 2019 FY | 785.87 Billion JPY | 5.58% |
| 2018 Q2 | 759.12 Billion JPY | 4.91% |
| 2018 Q4 | 744.36 Billion JPY | -7.87% |
| 2018 Q3 | 807.94 Billion JPY | 6.43% |
| 2018 Q1 | 723.59 Billion JPY | 9.92% |
| 2018 FY | 744.36 Billion JPY | 13.07% |
| 2017 Q2 | 686.82 Billion JPY | -3.65% |
| 2017 FY | 658.3 Billion JPY | -11.02% |
| 2017 Q3 | 704.47 Billion JPY | 2.57% |
| 2017 Q4 | 658.3 Billion JPY | -6.55% |
| 2017 Q1 | 712.83 Billion JPY | -3.65% |
| 2016 Q1 | 784.45 Billion JPY | -7.17% |
| 2016 FY | 739.84 Billion JPY | -12.45% |
| 2016 Q3 | 701.71 Billion JPY | -3.5% |
| 2016 Q4 | 739.84 Billion JPY | 5.43% |
| 2016 Q2 | 727.16 Billion JPY | -7.3% |
| 2015 Q3 | 850.78 Billion JPY | 10.87% |
| 2015 FY | 845.07 Billion JPY | 52.82% |
| 2015 Q4 | 845.07 Billion JPY | -0.67% |
| 2015 Q2 | 767.39 Billion JPY | 5.89% |
| 2015 Q1 | 724.74 Billion JPY | 0.0% |
| 2014 Q2 | 479.31 Billion JPY | -7.4% |
| 2014 FY | 553 Billion JPY | 21.77% |
| 2014 Q3 | 498.2 Billion JPY | 3.94% |
| 2014 Q1 | 517.64 Billion JPY | 19.73% |
| 2013 Q2 | 461.87 Billion JPY | 1.7% |
| 2013 FY | 454.13 Billion JPY | 2.28% |
| 2013 Q4 | 432.33 Billion JPY | -4.46% |
| 2013 Q3 | 452.53 Billion JPY | -2.02% |
| 2013 Q1 | 454.13 Billion JPY | 17.79% |
| 2012 Q4 | 385.54 Billion JPY | -12.11% |
| 2012 Q2 | 449.6 Billion JPY | 1.26% |
| 2012 FY | 444 Billion JPY | 4.13% |
| 2012 Q1 | 444 Billion JPY | -0.0% |
| 2012 Q3 | 438.66 Billion JPY | -2.43% |
| 2011 FY | 426.39 Billion JPY | -16.38% |
| 2011 Q1 | 426.39 Billion JPY | 3.64% |
| 2011 Q2 | 462.13 Billion JPY | 8.38% |
| 2011 Q3 | 467.29 Billion JPY | 1.12% |
| 2011 Q4 | 444.02 Billion JPY | -4.98% |
| 2010 Q1 | 509.91 Billion JPY | 4.02% |
| 2010 Q4 | 411.42 Billion JPY | -10.1% |
| 2010 Q3 | 457.65 Billion JPY | -3.99% |
| 2010 Q2 | 476.65 Billion JPY | -6.52% |
| 2010 FY | 509.91 Billion JPY | 17.23% |
| 2009 Q4 | 490.23 Billion JPY | -3.14% |
| 2009 Q3 | 506.15 Billion JPY | 0.51% |
| 2009 FY | 434.97 Billion JPY | 0.0% |
| 2009 Q2 | 503.58 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | -1395.052% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | -1308.353% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | -59967.141% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -1367581.547% |
| Novartis AG | 53.19 Billion USD | -1638.739% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -361281.648% |